Advanced search
Publication Cover
Emerging Microbes & Infections Volume 3, 2014 - Issue 1
Submit an article Journal homepage
1,353
Views
50
CrossRef citations to date
0
Altmetric
Original Articles

Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis

Jing LiThe Department of TB Control, Shanghai Municipal Centers for Disease Control and Prevention, Shanghai 200336, China
,
Xu GaoKey Laboratory of Medical Molecular Virology of the Ministries of Education and Health, Institutes of Biomedical Sciences and the Institute of Medical Microbiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
,
Tao LuoKey Laboratory of Medical Molecular Virology of the Ministries of Education and Health, Institutes of Biomedical Sciences and the Institute of Medical Microbiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
,
Jie WuThe Department of TB Control, Shanghai Municipal Centers for Disease Control and Prevention, Shanghai 200336, China
,
Gang SunKey Laboratory of Medical Molecular Virology of the Ministries of Education and Health, Institutes of Biomedical Sciences and the Institute of Medical Microbiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
,
Qingyun LiuKey Laboratory of Medical Molecular Virology of the Ministries of Education and Health, Institutes of Biomedical Sciences and the Institute of Medical Microbiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
,
Yuan JiangThe Department of TB Control, Shanghai Municipal Centers for Disease Control and Prevention, Shanghai 200336, China
,
Yangyi ZhangThe Department of TB Control, Shanghai Municipal Centers for Disease Control and Prevention, Shanghai 200336, China
,
Jian MeiThe Department of TB Control, Shanghai Municipal Centers for Disease Control and Prevention, Shanghai 200336, China
&
Qian GaoKey Laboratory of Medical Molecular Virology of the Ministries of Education and Health, Institutes of Biomedical Sciences and the Institute of Medical Microbiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, ChinaCorrespondence[email protected]
 show all
Pages 1-5 | Received 23 Sep 2015, Accepted 02 Nov 2015, Published online: 25 Jan 2019

  • Falzon D, Jaramillo E, Schünemann HJ et al.WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J2011;38: 516–528.
  • Maruri F, Sterling TR, Kaiga AW et al.A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother2012;67: 819–831.
  • World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response.Geneva: WHO, 2010.Available at http://www.who.int/tb/features_archive/m_xdrtb_facts/en/ (accessed 20 December 2013).
  • Aubry A, Pan XS, Fisher LM et al.Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother2004;48: 1281–1288.
  • Xu C, Kreiswirth BN, Sreevatsan S et al.Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis1996;174: 1127–1130.
  • Cabral JHM, Jackson AP, Smith CV et al.Crystal structure of the breakage–reunion domain of DNA gyrase. Nature1997;388: 903–906.
  • Piton J, Petrella S, Delarue M et al.Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS ONE2010;5: e12245.
  • Tretter EM, Schoeffler AJ, Weisfield SR et al.Crystal structure of the DNA gyrase GyrA N-terminal domain from Mycobacterium tuberculosis. Proteins2010;78: 492–495.
  • Aubry A, Veziris N, Cambau E et al.Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother2006;50: 104–112.
  • von Groll A, Martin A, Jureen P et al.Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother2009;53: 4498–4500.
  • Yin X, Yu Z.Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China. J Infect2010;61: 150.
  • Sirgel FA, Warren RM, Streicher EM et al.gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother2012;67: 1088–1093.
  • Malik S, Willby M, Sikes D et al.New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS ONE2012;7: e39754.
  • Pantel A, Petrella S, Veziris N et al.Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother2012;56: 1990–1996.
  • Kam KM, Yip CW, Cheung TL et al.Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist2006;12: 7–11.
  • Rustomjee R, Lienhardt C, Kanyok T et al.A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis2008;12: 128–138.
  • Ginsburg AS, Grosset JH, Bishai WR.Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis2003;3: 432–442.
  • Cui Z, Wang J, Lu J et al.Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infect Dis2011;11: 78.
  • McNerney R, Maeurer M, Abubakar I et al.Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis2012;205 Suppl 2: S147–S158.
  • Magdalena J, Vachée A, Supply P et al.Identification of a new DNA region specific for members of Mycobacterium tuberculosis complex. J Clin Microbiol1998;36: 937–943.
  • Moore DA, Evans CA, Gilman RH et al.Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med2006;355: 1539–1550.
  • Devasia RA, Blackman A, May C et al.Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother2009;63: 1173–1178.
  • World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs.Geneva: WHO, 2008.Available at http://www.who.int/tb/publications/2008/whohtmtb_2008_392/en/index.html (accessed 20 December 2013).
  • Da SPE, von Groll A, Martin A et al.Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol2011;63: 1–9.
  • van der Heijden YF, Maruri F, Blackman A et al.Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. Int J Antimicrob Agents2013;42: 232–237.
  • World Health Organization. Stop TB Dept.Treatment of tuberculosis: guidelines.Geneva: WHO, 2010.Available at https://extranet.who.int/iris/restricted/handle/10665/44165?locale=en.
  • Alffenaar JW, van Altena R, Bokkerink HJ et al.Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis2009;49: 1080–1082.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.